|1.||O'Donnell, Martha E: 11 articles (05/2014 - 09/2004)|
|2.||Kahle, Kristopher T: 8 articles (07/2015 - 09/2008)|
|3.||Anderson, Steven E: 7 articles (05/2014 - 09/2004)|
|4.||Staley, Kevin J: 7 articles (02/2011 - 11/2005)|
|5.||Sun, Dandan: 6 articles (07/2015 - 01/2003)|
|6.||Ben-Ari, Yehezkel: 6 articles (02/2015 - 08/2008)|
|7.||Lam, Tina I: 6 articles (05/2014 - 09/2004)|
|8.||Löscher, Wolfgang: 5 articles (01/2015 - 06/2010)|
|9.||Brandt, Claudia: 5 articles (01/2015 - 06/2010)|
|10.||Jensen, Frances E: 4 articles (04/2015 - 11/2005)|
09/01/2009 - "The obtained results provide further evidence that bumetanide may be beneficial for treating neonatal seizures, and that NKCC1 represents a potential target for antiepileptic interventions in the immature brain."
05/01/2015 - "Preclinical data suggest that the loop-diuretic bumetanide might be an effective treatment for neonatal seizures. "
11/01/2005 - "Our results provide evidence that NKCC1 facilitates seizures in the developing brain and indicate that bumetanide should be useful in the treatment of neonatal seizures."
02/25/2015 - "Moreover, the relative expression of the cation-chloride cotransporters (CCC) NKCC1 (Slc12a2) and KCC2 (Slc12a5), which are responsible for establishing the neuronal Cl(-) gradient that governs GABAergic inhibition were altered and the NKCC1 inhibitor bumetanide eliminated seizures in a subgroup of mice. "
05/01/2015 - "Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial."
11/01/1981 - "Bumetanide mobilizes peripheral edema effectively in most patients and leads to improvement in functional physical capacity. "
02/01/1997 - "The continuous infusion of the loop diuretic, bumetanide, has been shown to be effective in the treatment of severe refractory edema. "
08/01/2010 - "Edema formation was significantly more robust in young mice and was reduced with Bumetanide. "
02/11/2009 - "However, bumetanide (BUM), a diuretic blocker of Na(+)-K(+)-2Cl(-) channels, and L-644, 711, a nondiuretic anion channel inhibitor--both lacking antioxidant capabilities as well as reportedly ineffective against alcohol-dependent brain damage in vivo--reduced neither alcohol-induced neurotoxicity nor (with BUM) edema in HEC slices. "
10/01/2008 - "We investigated CBF and edema formation in a rat model of DKA and determined the effects of bumetanide, an inhibitor of Na-K-Cl cotransport. "
|3.||Autistic Disorder (Autism)
09/01/2015 - "Treatment with bumetanide combined with ABA training may result in a better outcome in children with autism than ABA training alone."
02/01/2015 - "The improvement of emotion processing by bumetanide reinforces the usefulness of bumetanide as a promising treatment to improve social interactions in autism. "
01/01/2012 - "Therefore, bumetanide is a promising novel therapeutic agent to treat autism. "
02/01/2015 - "In a previous double-blind randomized study, we have shown that the diuretic NKCC1 chloride importer antagonist bumetanide, that decreases (Cl-)i and reinforces GABAergic inhibition, reduces the severity of autism symptoms. "
09/01/2015 - "The purpose of this study was to investigate the therapeutic effects of combined bumetanide and applied behavior analysis (ABA) treatment in children with autism. "
03/01/2007 - "Bumetanide or genetic ablation of NKCC1 attenuated mitochondrial dysfunction and astrocyte death following ischemia. "
08/01/2004 - "Astrocytes showed marked swelling during ischemia in the absence of extracellular Ca2+, which was blocked by bumetanide. "
08/01/2004 - "Astrocytes showed rapid [Na+]i increases during ischemia and cell death was reduced to control levels by substitution of extracellular Na+ or Cl- or by perfusion with bumetanide, a selective Na-K-Cl cotransport (NKCC) blocker. "
01/24/2003 - "Artificial cerebral spinal fluid (aCSF) or 100 microM bumetanide in aCSF were continuously microdialyzed into left cortices either 1 h prior to ischemia plus 2-h ischemia, or only during 24-h reperfusion. "
02/01/1996 - "For the same protocol, the presence of bumetanide resulted in increased [Ca]i during ischemia and reperfusion (P < 0.05); these increases in [Ca]i are interpreted to be the result of increased Nai. "
01/01/2013 - "The primary objective of this study was to estimate a dose-response effect of IV bumetanide on urine output (UOP) in all patients that received 48 hours of therapy as well as in a subgroup of patients with heart failure (HF). "
02/01/1997 - "Heart failure patients receiving continuous infusions of bumetanide were monitored for the development of musculoskeletal symptoms. "
02/01/1997 - "To evaluate the characteristics of bumetanide-induced musculoskeletal symptoms during continuous i.v. infusion in patients with severe heart failure. "
11/01/1988 - "Four healthy subjects and six patients with congestive heart failure (CHF) were given 3 mg oral and intravenous doses of bumetanide in a random crossover fashion. "
11/01/1988 - "Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure."
|3.||Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)
|1.||Sodium-Restricted Diet (Diet, Sodium Restricted)
|5.||Heterologous Transplantation (Xenotransplantation)